Diaceutics PLC (LON:DXRX) Insider Buys £149.76 in Stock

Diaceutics PLC (LON:DXRX) insider Jordan Clark acquired 104 shares of Diaceutics stock in a transaction that occurred on Tuesday, January 28th. The shares were purchased at an average cost of GBX 144 ($1.79) per share, with a total value of £149.76 ($185.69).

Diaceutics Price Performance

LON DXRX opened at GBX 136.25 ($1.69) on Friday. Diaceutics PLC has a fifty-two week low of GBX 92.24 ($1.14) and a fifty-two week high of GBX 151 ($1.87). The stock’s 50-day moving average is GBX 130.24 and its two-hundred day moving average is GBX 128.62. The firm has a market cap of £115.09 million, a P/E ratio of -4,541.67 and a beta of 0.58. The company has a debt-to-equity ratio of 2.93, a current ratio of 4.85 and a quick ratio of 9.92.

Analyst Upgrades and Downgrades

DXRX has been the subject of a number of recent research reports. Canaccord Genuity Group reiterated a “buy” rating and set a GBX 160 ($1.98) price target on shares of Diaceutics in a report on Tuesday, December 17th. Canaccord Genuity Group reiterated a “buy” rating and issued a GBX 160 ($1.98) target price on shares of Diaceutics in a research note on Tuesday, December 17th.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.